Biotech entity
pharma is the sole category represented across all 1 tracked stories. GLP-1s is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 14 original sources each. Franco Stevanato appears in 1 tracked Biotech story from March 5, 2026.
Last mentioned: Mar 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. GLP-1s is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 14 original sources each. Franco Stevanato appears in 1 tracked Biotech story from March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Franco Stevanato. Shared-story counts are live from our verified record — not editorial picks.
Stevanato Group reported a 50% surge in GLP-1 related revenue for 2025, underscoring the massive impact of the weight-loss drug market on pharmaceutical supply chains. Conversely, medical device maker Pulmonx is undergoing a significant transition following a 50% turnover in its sales organization and a dip in U.S. quarterly revenue.
Franco Stevanato is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
